The pharma industry saw double-digit growth in patent filings for the second year in a row in 2018, with applications from the UK up by a fifth, according to the latest
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh